Treatment modalities and drug survival in a systemic sclerosis real-life patient cohort

被引：0
作者：
S. Panopoulos
Κ. Chatzidionysiou
M. G. Tektonidou
V. K. Bournia
A. A. Drosos
Stamatis-Nick C. Liossis
T. Dimitroulas
L. Sakkas
D. Boumpas
P. V. Voulgari
D. Daoussis
K. Thomas
G. Georgiopoulos
G. Vosvotekas
Α. Garyfallos
P. Sidiropoulos
G. Bertsias
D. Vassilopoulos
P. P. Sfikakis
机构：
[1] National and Kapodistrian University of Athens,Joint Rheumatology Program, 1st Department of Propedeutic Internal Medicine
[2] School of Medicine,Rheumatology Unit
[3] Laikon General Hospital,Rheumatology Clinic, Department of Internal Medicine, Medical School
[4] University of Ioannina,Division of Rheumatology, Department of Internal Medicine
[5] Patras University Hospital,4th Department of Internal Medicine, Hippokration General Hospital, Medical School
[6] Medical School,Department of Rheumatology, Faculty of Medicine, School of Health Sciences
[7] University of Patras,Joint Rheumatology Program, 4th Department of Internal Medicine
[8] Aristotle University of Thessaloniki,Joint Rheumatology Program, Clinical Immunology
[9] University of Thessaly,Rheumatology Unit, 2nd Department of Medicine and Laboratory
[10] National and Kapodistrian University of Athens,1st Department of Medicine
[11] School of Medicine,Department of Clinical Rheumatology, Clinical Immunology and Allergy
[12] Attikon University Hospital,undefined
[13] National and Kapodistrian University of Athens,undefined
[14] School of Medicine,undefined
[15] Hippokration General Hospital,undefined
[16] Aristotle University of Thessaloniki,undefined
[17] School of Medicine,undefined
[18] University General Hospital of Thessaloniki AHEPA,undefined
[19] Faculty of Medicine-University of Crete,undefined
来源：
Arthritis Research & Therapy | / 22卷
关键词：
Systemic sclerosis; Treatment patterns; Drug survival; Cohort study;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 178 条
  • [1] Varga J(2017)Pathogenesis of systemic sclerosis: recent insights of molecular and cellular mechanisms and therapeutic opportunities J Scleroderma Relat Disord 2 137-152
  • [2] Trojanowska M(2010)Causes and risk factors for death in systemic sclerosis: a study from the EULAR Scleroderma Trials and Research (EUSTAR) database Ann Rheum Dis 69 1809-1815
  • [3] Kuwana M(2011)Life expectancy, standardized mortality ratios, and causes of death in six rheumatic diseases in Hong Kong, China Arthritis Rheum 63 1182-1189
  • [4] Tyndall AJ(2019)Overall and sex- and disease subtype-specific mortality in patients with systemic sclerosis: an updated meta-analysis Z Rheumatol 78 195-201
  • [5] Bannert B(2012)Trends in mortality in patients with systemic sclerosis over 40 years: a systematic review and meta-analysis of cohort studies Rheumatol (Oxford). 51 1017-1026
  • [6] Vonk M(2017)Mapping and predicting mortality from systemic sclerosis Ann Rheum Dis 76 1897-1905
  • [7] Airo P(2013)Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study Ann Rheum Dis 72 1217-1220
  • [8] Cozzi F(2016)Safety and efficacy of subcutaneous tocilizumab in adults with systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial Lancet. 387 2630-2640
  • [9] Carreira PE(2015)Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group Ann Rheum Dis 74 1188-1194
  • [10] Mok CC(2018)Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review Autoimmun Rev 17 582-587
12345678910